-
公开(公告)号：US09630922B2
公开(公告)日：2017-04-25
申请号：US15130613
申请日：2016-04-15
Applicant: Forma Therapeutics, Inc.
Inventor： Pui Yee Ng , Heather Davis , Kenneth W. Bair , David S. Millan , Aleksandra Rudnitskaya , Xiaozhang Zheng , Bingsong Han , Nicholas Barczak , David R. Lancia, Jr.
IPC: C07D221/20 , C07D403/04 , C07D209/96 , C07D401/04 , C07D417/06 , C07D519/00 , C07D401/06 , C07D413/06 , C07D405/04 , C07D471/04 , C07D497/10 , C07D491/107 , C07D405/06 , C07D403/06 , C07D405/10
CPC classification number: C07D209/96 , C07D221/20 , C07D401/04 , C07D401/06 , C07D403/04 , C07D403/06 , C07D405/04 , C07D405/06 , C07D405/10 , C07D413/06 , C07D417/06 , C07D471/04 , C07D491/107 , C07D497/10 , C07D519/00
Abstract: The present invention is directed to inhibitors of histone deacetylases (HDACs) such as HDAC6, and their use in the treatment of diseases such as cell proliferative diseases (e.g., cancer), neurological (e.g., neurodegenerative disease or neurodevelopmental disease), inflammatory or autoimmune disease, infection, metabolic disease, hematologic disease, or cardiovascular disease.
-
![[6,6] FUSED BICYCLIC HDAC8 INHIBITORS](/abs-image/US/2017/03/09/US20170066729A1/abs.jpg.150x150.jpg)
公开(公告)号：US20170066729A1
公开(公告)日：2017-03-09
申请号：US15255817
申请日：2016-09-02
Applicant: Forma Therapeutics, Inc.
Inventor： Xiaozhang Zheng , Pui Yee Ng , Jennifer R. Thomason , Mary-Margaret Zablocki , Bingsong Han , Nicholas Barczak , Cuixian Liu , Aleksandra Rudnitskaya , David R. Lancia, JR. , Kenneth W. Bair
IPC: C07D265/36 , C07D413/06 , C07D401/04 , C07D279/16 , C07D265/34 , C07D413/10 , C07D471/04 , C07D417/06 , C07D513/04 , C07D487/04 , C07D413/12 , C07D491/107
CPC classification number: C07D265/36 , C07D265/34 , C07D279/14 , C07D279/16 , C07D401/04 , C07D413/06 , C07D413/10 , C07D413/12 , C07D417/06 , C07D471/04 , C07D487/04 , C07D491/107 , C07D513/04
Abstract: The present invention is directed to compounds of Formula I: and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers or thereof, wherein R1, R2, R2′, L, X, W, Y1, Y2, Y3, and Y4 are described herein.
Abstract translation: 本发明涉及式I化合物及其药学上可接受的盐，前药，溶剂合物，水合物，互变异构体或异构体，其中R1，R2，R2'，L，X，W，Y1，Y2，Y3和 Y4。
-
公开(公告)号：US20160304462A1
公开(公告)日：2016-10-20
申请号：US15130613
申请日：2016-04-15
Applicant: Forma Therapeutics, Inc.
Inventor： Pui Yee Ng , Heather Davis , Kenneth W. Bair , David S. Millan , Aleksandra Rudnitskaya , Xiaozhang Zheng , Bingsong Han , Nicholas Barczak , David R. Lancia, JR.
IPC: C07D221/20 , C07D403/04 , C07D209/96 , C07D401/04 , C07D417/06 , C07D519/00 , C07D401/06 , C07D413/06 , C07D405/04 , C07D471/04 , C07D497/10 , C07D491/107 , C07D405/06 , C07D403/06
CPC classification number: C07D209/96 , C07D221/20 , C07D401/04 , C07D401/06 , C07D403/04 , C07D403/06 , C07D405/04 , C07D405/06 , C07D405/10 , C07D413/06 , C07D417/06 , C07D471/04 , C07D491/107 , C07D497/10 , C07D519/00
Abstract: The present invention is directed to inhibitors of histone deacetylases (HDACs) such as HDAC6, and their use in the treatment of diseases such as cell proliferative diseases (e.g., cancer), neurological (e.g., neurodegenerative disease or neurodevelopmental disease), inflammatory or autoimmune disease, infection, metabolic disease, hematologic disease, or cardiovascular disease.
Abstract translation: 本发明涉及组蛋白脱乙酰酶（HDAC）如HDAC6的抑制剂及其在治疗诸如细胞增殖性疾病（例如癌症），神经系统疾病（例如神经变性疾病或神经发育疾病），炎性或自身免疫性疾病 疾病，感染，代谢疾病，血液病或心血管疾病。
-
公开(公告)号：US20200331847A1
公开(公告)日：2020-10-22
申请号：US16689252
申请日：2019-11-20
Applicant: FORMA Therapeutics, Inc.
Inventor： Kenneth W. Bair , Nicholas Barczak , Bingsong Han , David R. Lancia, JR. , Cuixian Liu , Matthew W. Martin , Pui Yee Ng , Aleksandra Rudnitskaya , Jennifer R. Thomason , Mary-Margaret Zablocki , Xiaozhang Zheng
IPC: C07C259/06 , A61K31/185 , C07D221/20 , A61K31/438 , A61K31/277 , C07D209/44 , A61K31/4035 , C07D295/155 , A61K31/451 , C07D471/10 , A61K31/435 , C07D487/10 , A61K31/407 , C07D495/10 , A61K31/397 , C07D235/14 , A61K31/4184 , C07D233/68 , A61K31/417 , C07D213/56 , A61K31/44 , C07D241/08 , A61K31/495 , C07D417/04 , A61K31/4439 , A61K31/5377 , C07D471/04 , C07D401/14 , C07D213/75 , C07D213/81 , C07D215/12 , C07D317/68 , C07D231/14 , C07D231/18 , C07D233/36 , C07D233/38 , C07D333/70 , C07D401/04 , C07D401/12 , C07D235/30 , C07D239/20 , C07D239/22 , C07D405/12 , C07D409/04 , C07D409/12 , C07D241/12 , C07D417/12 , C07D249/18 , C07D257/04 , C07D261/18 , C07D487/04 , C07D487/08 , C07D491/10 , C07D207/10 , C07D493/08 , C07D207/267 , C07D498/04 , C07D209/08 , C07D277/56 , C07D209/42 , C07D209/46 , C07D513/10 , C07D211/16 , C07D211/58 , C07D295/192 , C07D213/65 , C07D307/68
Abstract: The present invention relates to inhibitors of histone deacetylases, in particular HDAC8, that are useful for the treatment of cancer and other diseases and disorders, as well as the synthesis and applications of said inhibitors.
-
公开(公告)号：US20190084945A1
公开(公告)日：2019-03-21
申请号：US16202207
申请日：2018-11-28
Applicant: FORMA Therapeutics, Inc.
Inventor： Jennifer Lee , Nicholas Barczak , Jaime A. Escobedo , Chiara Conti , Bingsong Han , David R. Lancia, JR. , Cuixian Liu , Matthew W. Martin , Pui Yee Ng , Aleksandra Rudnitskaya , Jennifer R. Thomason , Xiaozhang Zheng
IPC: C07D263/58 , C07D401/04 , C07C53/06 , C07D235/30 , C07D221/20 , C07D209/54 , C07D209/40 , A61K45/06 , A61K31/5383 , A61K31/5377 , A61K31/52 , A61K31/506 , A61K31/4985 , A61K31/4709 , A61K31/4439 , A61K31/438 , A61K31/437 , A61K31/435 , A61K31/428 , C07D498/04 , C07D491/107 , C07D491/056 , C07D487/04 , C07D473/00 , C07D417/06 , C07D413/14 , C07D413/12 , C07D413/06 , C07D405/04 , C07D403/06 , C07D403/04 , C07D401/14 , C07D401/06 , A61K31/427 , A61K31/4245 , A61K31/423 , A61K31/422 , A61K31/4192 , A61K31/4188 , A61K31/4184 , A61K31/4178 , A61K31/404 , A61K31/403 , A61P35/00 , C07D277/82
CPC classification number: C07D263/58 , A61K31/403 , A61K31/404 , A61K31/4178 , A61K31/4184 , A61K31/4188 , A61K31/4192 , A61K31/422 , A61K31/423 , A61K31/4245 , A61K31/427 , A61K31/428 , A61K31/435 , A61K31/437 , A61K31/438 , A61K31/4439 , A61K31/4709 , A61K31/4985 , A61K31/506 , A61K31/52 , A61K31/5377 , A61K31/5383 , A61K45/06 , A61P35/00 , C07C53/06 , C07D209/40 , C07D209/54 , C07D221/20 , C07D235/30 , C07D277/82 , C07D401/04 , C07D401/06 , C07D401/14 , C07D403/04 , C07D403/06 , C07D405/04 , C07D413/06 , C07D413/12 , C07D413/14 , C07D417/06 , C07D473/00 , C07D487/04 , C07D491/056 , C07D491/107 , C07D498/04
Abstract: The present invention provides methods and uses of inhibitors of histone deacetylase 11 (HDAC11) in the treatment of diseases and/or disorders, such as, for example, cell proliferative diseases.
-
Patent Agency Ranking
![[6,6] FUSED BICYCLIC HDAC8 INHIBITORS](/abs-image/US/2018/12/13/US20180354919A1/abs.jpg.150x150.jpg)
公开(公告)号：US20180354919A1
公开(公告)日：2018-12-13
申请号：US16003861
申请日：2018-06-08
Applicant: FORMA Therapeutics, Inc.
Inventor： Xiaozhang Zheng , Pui Yee Ng , Jennifer R. Thomason , Mary-Margaret Zablocki , Bingsong Han , Nicholas Barczak , Cuixian Liu , Aleksandra Rudnitskaya , David R. Lancia, JR. , Kenneth W. Bair
IPC: C07D265/36 , C07D265/34 , C07D487/04 , C07D513/04 , C07D417/06 , C07D471/04 , C07D413/10 , C07D279/14 , C07D279/16 , C07D401/04 , C07D413/06 , C07D413/12 , C07D491/107
CPC classification number: C07D265/36 , C07D265/34 , C07D279/14 , C07D279/16 , C07D401/04 , C07D413/06 , C07D413/10 , C07D413/12 , C07D417/06 , C07D471/04 , C07D487/04 , C07D491/107 , C07D513/04
Abstract: The present invention is directed to compounds of Formula I: and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers or thereof, wherein R1, R2, R2′, L, X, W, Y1, Y2, Y3, and Y4 are described herein.
-
公开(公告)号：US09745253B2
公开(公告)日：2017-08-29
申请号：US15067605
申请日：2016-03-11
Applicant: Forma Therapeutics, Inc.
Inventor： Kenneth W Bair , Nicholas Barczak , Bingsong Han , David R. Lancia, Jr. , Cuixian Liu , Matthew W Martin , Pui Yee Ng , Aleksandra Rudnitskaya , Jennifer R Thomason , Mary Margaret Zablocki , Xiaozhang Zheng
IPC: C07C259/06 , C07D401/14 , C07D213/81 , C07D215/12 , C07D317/68 , C07D231/14 , C07D231/18 , C07D233/36 , C07D233/38 , C07D333/70 , C07D401/04 , C07D401/12 , C07D235/30 , C07D239/20 , C07D239/22 , C07D307/68 , C07D213/65 , C07D295/192 , C07D211/58 , C07D211/16 , C07D513/10 , C07D209/46 , C07D209/42 , C07D277/56 , C07D209/08 , C07D498/04 , C07D207/267 , C07D493/08 , C07D207/10 , C07D491/10 , C07D487/08 , C07D487/04 , C07D261/18 , C07D213/75 , C07D257/04 , C07D249/18 , C07D417/12 , C07D241/12 , C07D409/12 , C07D409/04 , C07D405/12 , A61K31/407 , C07D471/04 , A61K31/4439 , C07D417/04 , A61K31/495 , C07D241/08 , A61K31/44 , C07D213/56 , C07D233/68 , A61K31/4184 , C07D235/14 , A61K31/397 , C07D495/10 , A61K31/5377 , C07D487/10 , A61K31/435 , C07D471/10 , A61K31/451 , C07D295/155 , A61K31/4035 , C07D209/44 , A61K31/277 , A61K31/438 , C07D221/20 , A61K31/185 , A61K31/417
CPC classification number: C07C259/06 , A61K31/185 , A61K31/277 , A61K31/397 , A61K31/4035 , A61K31/407 , A61K31/417 , A61K31/4184 , A61K31/435 , A61K31/438 , A61K31/44 , A61K31/4439 , A61K31/451 , A61K31/495 , A61K31/5377 , C07D207/10 , C07D207/267 , C07D209/08 , C07D209/42 , C07D209/44 , C07D209/46 , C07D211/16 , C07D211/58 , C07D213/56 , C07D213/65 , C07D213/75 , C07D213/81 , C07D215/12 , C07D221/20 , C07D231/14 , C07D231/18 , C07D233/36 , C07D233/38 , C07D233/68 , C07D235/14 , C07D235/30 , C07D239/20 , C07D239/22 , C07D241/08 , C07D241/12 , C07D249/18 , C07D257/04 , C07D261/18 , C07D277/56 , C07D295/155 , C07D295/192 , C07D307/68 , C07D317/68 , C07D333/70 , C07D401/04 , C07D401/12 , C07D401/14 , C07D405/12 , C07D409/04 , C07D409/12 , C07D417/04 , C07D417/12 , C07D471/04 , C07D471/10 , C07D487/04 , C07D487/08 , C07D487/10 , C07D491/10 , C07D493/08 , C07D495/10 , C07D498/04 , C07D513/10
Abstract: The present invention relates to inhibitors of histone deacetylases, in particular HDAC8, that are useful for the treatment of cancer and other diseases and disorders, as well as the synthesis and applications of said inhibitors.
-
公开(公告)号：US10508077B2
公开(公告)日：2019-12-17
申请号：US16387937
申请日：2019-04-18
Applicant: FORMA Therapeutics, Inc.
Inventor： Kenneth W. Bair , Nicholas Barczak , Bingsong Han , David R. Lancia, Jr. , Cuixian Liu , Matthew W. Martin , Pui Yee Ng , Aleksandra Rudnitskaya , Jennifer R. Thomason , Mary-Margaret Zablocki , Xiaozhang Zheng
IPC: C07C259/06 , C07D471/04 , A61K31/5377 , A61K31/4439 , C07D417/04 , A61K31/495 , C07D241/08 , A61K31/44 , C07D213/56 , A61K31/417 , C07D233/68 , A61K31/4184 , C07D235/14 , A61K31/397 , A61K31/407 , C07D487/10 , A61K31/435 , C07D471/10 , A61K31/451 , C07D295/155 , A61K31/4035 , C07D209/44 , A61K31/277 , A61K31/438 , A61K31/185 , C07D495/10 , C07D221/20 , C07D307/68 , C07D213/65 , C07D295/192 , C07D211/58 , C07D211/16 , C07D513/10 , C07D209/46 , C07D209/42 , C07D277/56 , C07D209/08 , C07D498/04 , C07D207/267 , C07D493/08 , C07D207/10 , C07D491/10 , C07D487/08 , C07D487/04 , C07D261/18 , C07D257/04 , C07D249/18 , C07D417/12 , C07D241/12 , C07D409/12 , C07D409/04 , C07D405/12 , C07D239/22 , C07D239/20 , C07D235/30 , C07D401/12 , C07D401/04 , C07D333/70 , C07D233/38 , C07D233/36 , C07D231/18 , C07D231/14 , C07D317/68 , C07D215/12 , C07D213/81 , C07D213/75 , C07D401/14
Abstract: The present invention relates to inhibitors of histone deacetylases, in particular HDAC8, that are useful for the treatment of cancer and other diseases and disorders, as well as the synthesis and applications of said inhibitors.
-
![[6,6] FUSED BICYCLIC HDAC8 INHIBITORS](/abs-image/US/2019/10/10/US20190308946A1/abs.jpg.150x150.jpg)
公开(公告)号：US20190308946A1
公开(公告)日：2019-10-10
申请号：US16449675
申请日：2019-06-24
Applicant: FORMA Therapeutics, Inc.
Inventor： Xiaozhang Zheng , Pui Yee Ng , Jennifer R. Thomason , Mary-Margaret Zablocki , Bingsong Han , Nicholas Barczak , Cuixian Liu , Aleksandra Rudnitskaya , David R. Lancia, JR. , Kenneth W. Bair
IPC: C07D265/36 , C07D279/14 , C07D265/34 , C07D487/04 , C07D513/04 , C07D417/06 , C07D413/12 , C07D413/10 , C07D491/107 , C07D279/16 , C07D401/04 , C07D413/06 , C07D471/04
Abstract: The present invention is directed to compounds of Formula I: and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers or thereof, wherein R1, R2, R2′, L, X, W, Y1, Y2, Y3, and Y4 are described herein.
-
公开(公告)号：US20190241506A1
公开(公告)日：2019-08-08
申请号：US16387937
申请日：2019-04-18
Applicant: FORMA Therapeutics, Inc.
Inventor： Kenneth W. Bair , Nicholas Barczak , Bingsong Han , David R. Lancia, JR. , Cuixian Liu , Matthew W. Martin , Pui Yee Ng , Aleksandra Rudnitskaya , Jennifer R. Thomason , Mary-Margaret Zablocki , Xiaozhang Zheng
IPC: C07C259/06 , C07D471/04 , A61K31/5377 , A61K31/4439 , C07D417/04 , A61K31/495 , C07D241/08 , A61K31/44 , C07D213/56 , A61K31/417 , C07D233/68 , A61K31/4184 , C07D235/14 , A61K31/397 , A61K31/407 , C07D487/10 , A61K31/435 , C07D471/10 , A61K31/451 , C07D295/155 , A61K31/4035 , C07D209/44 , A61K31/277 , A61K31/438 , A61K31/185 , C07D495/10 , C07D221/20 , C07D307/68 , C07D213/65 , C07D295/192 , C07D211/58 , C07D211/16 , C07D513/10 , C07D209/46 , C07D209/42 , C07D277/56 , C07D209/08 , C07D498/04 , C07D207/267 , C07D493/08 , C07D207/10 , C07D491/10 , C07D487/08 , C07D487/04 , C07D261/18 , C07D257/04 , C07D249/18 , C07D417/12 , C07D241/12 , C07D409/12 , C07D409/04 , C07D405/12 , C07D239/22 , C07D239/20 , C07D235/30 , C07D401/12 , C07D401/04 , C07D333/70 , C07D233/38 , C07D233/36 , C07D231/18 , C07D231/14 , C07D317/68 , C07D215/12 , C07D213/81 , C07D213/75 , C07D401/14
Abstract: The present invention relates to inhibitors of histone deacetylases, in particular HDAC8, that are useful for the treatment of cancer and other diseases and disorders, as well as the synthesis and applications of said inhibitors.
-
-
-
-
-
-
-
-
-
Search Results
23
records
(took 0.027 seconds)
